Anavex Life Sciences Corp (AVXL)

[tredenwater2]

“(2) We appreciate this new guidance and believe this opens another possible pathway for us to move forward in parallel to the initiated process of market authorization application to the European Medicine Agency, EMA, for blarcamesine for the treatment of Alzheimer’s disease which is already underway.”

Welcome back Abew! I know we have said it before but “next year this time” we should be in for a real treat. I entered into this stock in 2015 and after a decade of trials, 2025 WILL be the year for Alzheimer’s approval.

Looks like from the above statement that the Fda submission of an NDA (at least preparing large portions) will be happening in parallel.

The shorts were successful in scaring and driving out retail many times along the way, Im just glad you were able to reenter at a lower price.

Cheers

Tred